Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of AR-13503 Implant in nAMD and DME
NCT03835884Phase 1Completed
- Sponsor
- Aerie Pharmaceuticals
- Start
- Jun 2019
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of netarsudil-M1 in neovascular age-related macular degeneration (NVAMD) and diabetic macular edema (DME) (4 arms), sponsored by Aerie Pharmaceuticals. Primary endpoint: Treatment-Emergent Adverse Events at 24 weeks. Started Jun 2019; status: completed.
02
Drugs
netarsudil-M1
03
Conditions
neovascular age-related macular degeneration (NVAMD)diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT03835884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03835884.